



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Madeleine M. JOULLIÉ *et al.*

Appl. No.: 09/767,080

Filed: January 22, 2001

For: **Deoxo-Proline-Containing  
Tamandarin and Didemnin  
Analog, Dehydro-Proline -  
Containing Analog, and  
Methods of Making and Using  
Them**

Confirmation No.: 5576

Art Unit: 1653

Examiner: Abdel A. Mohamed

Atty. Docket: 1694.0640001

### Supplemental Information Disclosure Statement

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450  
Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of the documents are provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior

art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

Attached is our PTO-2038 Credit Card Payment Form in the amount of \$444.00 in payment of the fee (\$180.00) under 37 C.F.R. § 1.17(p).

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Matthew J. Dowd  
Agent for Applicants  
Registration No. 47,534

Date: September 30, 2004  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

1694.0640001

APPLICATION NO.

09/767,080

APPLICANT(S)

Madeleine M. JOULLIÉ, *et al.*

FILING DATE

January 22, 2001

ART UNIT

1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	5,137,870	8/11/92	Rinehart, Kenneth L.	514	10	2/20/90
	AB	2003/0104991 A1	6/05/03	Joullie, M. and Liang, B.	514	9	10/25/02
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Vervoort, H., <i>et al.</i> , "Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae," J. Org. Chem. 65:782-792, American Chemical Society (2000)
	AS	1	Joullie, M. M., <i>et al.</i> , "Total Synthesis of (-)-Tamandarin B," Tetrahedron Letters 41:9373-9376 Elsevier Science Ltd. (2000)
	AT	1	Liang, B., <i>et al.</i> , "Total Synthesis of [(2S)-Hiv <sup>2</sup> ]Didemnin M," J. Org. Chem. 65:4762-4765, American Chemical Society (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1694.0640001APPLICATION NO.  
09/767,080APPLICANT(S)  
Madeleine M. JOULLIÉ, *et al.*FILING DATE  
January 22, 2001ART UNIT  
1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>2</u>	Crews, C. M., <i>et al.</i> , "Didemnin Binds to the Protein Palmitoyl Thioesterase Responsible for Infantile Neuronal Ceroid Lipofuscinosis," Proc. Natl. Acad. Sci. USA 93:4316-4319 Natl. Acad. Sci. (1996)
	AS	<u>2</u>	Supplementary Partial European Search Report, Application No. EP 01924886.3-2117-US0111607, 07-12-2004
	AT	<u>2</u>	

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.